Indivior PLC

Executive Summary

Indivior PLC is a pharmaceutical company specializing in treatments for addiction and mental illness, with a primary focus on opioid use disorder (OUD). Its commercial portfolio includes SUBOXONE® (buprenorphine/naloxone) sublingual film and SUBLOCADE® (buprenorphine extended-release) injection. While facing headwinds from generic competition and legal challenges, the company continues to generate significant revenue from its OUD franchise. Recent pipeline setbacks, including the termination and withdrawal of two Phase 3 trials for SUBLOCADE, underscore the risks in its development efforts. However, Indivior remains a leading player in medication-assisted treatment, with opportunities from expanded patient access and potential label expansions. The company's financial health and ability to navigate patent expirations and litigation will be crucial for its long-term growth.

Upcoming Catalysts (preview)

• Q2 2026Resolution of ongoing patent litigation for SUBOXONE film80% success
• Q4 2026FDA decision on new formulation or label expansion for SUBLOCADE50% success
• Q2 2026Q2 2026 earnings report showing market share trends100% success